ACAD is dirt cheap: aproval is almost a certainty. If this is efective for Alzheimer's psicosis, bipolar disorder, Schizophrenia, depresion, dementia and a large etcetera you can give watever multiple you chose to the MM$300 in sales for parkinsons indication peak sales. ¿5B? ¿10B?
The fact that they are working towards establishing their own sales force says more about this peak sales figure (no partner bigger margins).
If you add Europe, Japan and the rest of the world to the picture and the fact that this could be sold as a profilactic as you got an answer: This can be a megablockbuster.
Pfizer is for Viagra and Lipitor, Gilead coctel for AIDS, Alexion on SOLIRIS, Next is Acadia with Pimavanserin. 100B market cap company.
It is estimated that the number of people with Parkinson's alone will double to 9.3 million people by 2030. Add all the possible other indications . . . and your head could blow-up calculating the income potential of Pima.